NasdaqGS - Delayed Quote • USD
Dyne Therapeutics, Inc. (DYN)
At close: April 23 at 4:00 PM EDT
After hours: April 23 at 4:05 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 7 | 7 | 7 | 6 |
Avg. Estimate | -0.8 | -0.81 | -3.29 | -3.27 |
Low Estimate | -0.83 | -0.87 | -3.6 | -4.48 |
High Estimate | -0.75 | -0.7 | -2.82 | -2.19 |
Year Ago EPS | -0.78 | -1.08 | -3.95 | -3.29 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 5 | 5 |
Avg. Estimate | -- | -- | -- | 21.45M |
Low Estimate | -- | -- | -- | -- |
High Estimate | -- | -- | -- | 105.07M |
Year Ago Sales | -- | -- | -- | -- |
Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.77 | -0.81 | -0.83 | -0.92 |
EPS Actual | -0.78 | -1.08 | -0.99 | -1.09 |
Difference | -0.01 | -0.27 | -0.16 | -0.17 |
Surprise % | -1.30% | -33.30% | -19.30% | -18.50% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.8 | -0.81 | -3.29 | -3.27 |
7 Days Ago | -0.8 | -0.81 | -3.29 | -3.27 |
30 Days Ago | -0.8 | -0.8 | -3.27 | -3.17 |
60 Days Ago | -0.71 | -0.71 | -3.14 | -2.63 |
90 Days Ago | -0.68 | -0.68 | -2.85 | -2.52 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | 1 | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | DYN | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -2.60% | -- | -- | 0.40% |
Next Qtr. | 25.00% | -- | -- | 9.90% |
Current Year | 16.70% | -- | -- | 4.30% |
Next Year | 0.60% | -- | -- | 13.40% |
Next 5 Years (per annum) | -- | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | Oppenheimer: Outperform to Outperform | 3/26/2024 |
Maintains | Chardan Capital: Buy to Buy | 3/8/2024 |
Maintains | Guggenheim: Buy to Buy | 3/7/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 3/6/2024 |
Maintains | Stifel: Buy to Buy | 3/6/2024 |
Maintains | Piper Sandler: Overweight to Overweight | 3/6/2024 |
Related Tickers
RNA Avidity Biosciences, Inc.
25.14
+4.06%
APGE Apogee Therapeutics, Inc.
49.77
+2.32%
EWTX Edgewise Therapeutics, Inc.
15.65
+3.78%
MLTX MoonLake Immunotherapeutics
43.25
+5.44%
MRUS Merus N.V.
40.82
+0.91%
SWTX SpringWorks Therapeutics, Inc.
44.00
+2.59%
ACLX Arcellx, Inc.
54.44
+4.69%
KYMR Kymera Therapeutics, Inc.
35.71
+3.96%
AVBP ArriVent BioPharma, Inc.
15.77
-0.82%
RVMD Revolution Medicines, Inc.
36.26
-0.47%